Latest Breast cancer treatment Stories
An international team of scientists, including four at Simon Fraser University, has made a discovery that will change the way the most deadly form of breast cancer is treated. The journal Nature has just published the team's findings online in the paper The clonal and mutational evolution spectrum of primary triple negative breast cancers. The study is the largest genetic analysis of what were thought to be triple negative breast cancer tumors. The 59 scientists involved in this...
The new model may provide scientists with a better understanding of the disease and help with developing effective interventions Inflammatory breast cancer (IBC) is a very aggressive, often misunderstood type of cancer that is diagnosed more frequently in younger women compared with other types of breast cancer. The five-year survival rate is between 25 and 50 percent—significantly lower than the survival rate for other types of breast cancer. The reason for the poor prognosis is that...
Long-term follow-up of a phase II clinical trial showed encouraging survival in some patients with stage 3B/4 non-small cell lung cancer treated with belagenpumatucel-L, a therapeutic vaccine. The findings were presented here at the AACR Annual Meeting 2012, held March 31 - April 4. "This is a novel immunotherapy that appears to show unusually long survival in some patients," said Lyudmila Bazhenova, M.D., associate clinical professor at the University of California-San Diego Moores Cancer...
Researchers and doctors at the North Shore-LIJ Health System and the Feinstein Institute for Medical Research have discovered that blood can help determine the best treatment plan for patients with ovarian cancer. More specifically, a genetic marker embedded in deoxyribonucleic acid (DNA), called microRNA, indicates if a patient with ovarian cancer has a benign or cancerous tumor, and that she will benefit from chemotherapy after surgery on the tumor. This data will be presented at the...
The findings suggest that new therapies targeting estrogen's metabolism may help prevent or treat lung cancer The hormone estrogen may help promote lung cancer— including compounding the effects of tobacco smoke on the disease—pointing towards potential new therapies that target the hormone metabolism, according to new research presented at the AACR Annual Meeting 2012 on Tuesday, April 3 by scientists at Fox Chase Cancer Center in Philadelphia. "This research provides the link...
Aberrations in translation regulators associated with hormone receptor-positive disease survival Four proteins involved in translation, the final step of general protein production, are associated with poor prognosis in hormone-receptor-positive breast cancer when they are dysregulated, researchers reported at the AACR Annual Meeting 2012. All of the aberrantly activated translational proteins are regulated by the PI3K/mTOR molecular signaling pathway, which has been implicated in...
Scientists at Washington University School of Medicine in St. Louis are using powerful DNA sequencing technology not only to identify mutations at the root of a patient's tumor – considered key to personalizing cancer treatment – but to map the genetic evolution of disease and monitor response to treatment. "We're finding clinically relevant information in the tumor samples we're sequencing for discovery-oriented research studies," says Elaine Mardis, PhD, co-director of The Genome...
At the time of diagnosis, the majority of breast cancers are categorized as estrogen-receptor positive, or hormone sensitive, which means their cancerous cells may need estrogen to grow. Patients with this type of cancer often respond favorably to treatments called aromatase inhibitors, like tamoxifen, which cause cell death by preventing estrogen from reaching the cancerous cells. Over time, however, the disease often becomes resistant to estrogen deprivation from the drugs—making...
CHICAGO, April 2, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results of three preclinical studies focused on c-MET, a receptor tyrosine kinase that, when it functions normally, plays a key role in transmitting signals within a cell. Abnormalities in c-MET function and signaling have been found in many types of cancer including lung, breast, prostate, gastric, esophageal and renal cancers. Two of the abstracts (#2734 and #2738) assess the anti-cancer...
Low oxygen levels in tumors can be used to predict cancer recurrence in men with intermediate-risk prostate cancer even before they receive radiation therapy. The clinical research, led by radiation oncologists at the Princess Margaret Hospital (PMH) Cancer Program, University Health Network (UHN) is published online today in Clinical Cancer Research, a journal of the American Association for Cancer Research (doi: 10.1158/1078-0432.CCR-11-2711). "We've not only shown that men do worse...
